Skin allograft maintenance in a new synchimeric model system of tolerance

被引:56
作者
Iwakoshi, NN
Markees, TG
Turgeon, N
Thornley, T
Cuthbert, A
Leif, J
Phillips, NE
Mordes, JP
Greiner, DL
Rossini, AA
机构
[1] Univ Massachusetts, Sch Med, Diabet Div, Dept Med, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Program Immunol & Virol, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA
[4] Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA
关键词
D O I
10.4049/jimmunol.167.11.6623
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Treatment of mice with a single donor-specific transfusion plus a brief course of anti-CD154 mAb uniformly induces donor-specific transplantation tolerance characterized by the deletion of alloreactive CD8(+) T cells. Survival of islet allografts in treated mice is permanent, but skin grafts eventually fail unless recipients are thymectomized. To analyze the mechanisms underlying tolerance induction, maintenance, and failure in euthymic mice we created a new analytical system based on allo-TCR-transgenic hemopoietic chimeric graft recipients. Chimeras were CBA (H-2(k)) mice engrafted with small numbers of syngeneic TCR-transgenic KB5 bone marrow cells. These mice subsequently circulated a self-renewing trace population of anti-H-2(b)-alloreactive CD8(+) T cells maturing in a normal microenvironment. With this system, we studied the maintenance of H-2(b) allografts in tolerized mice. We documented that alloreactive CD8(+) T cells deleted during tolerance induction slowly returned toward pretreatment levels. Skin allograft rejection in this system occurred in the context of 1) increasing numbers of alloreactive CD8(+) cells; 2) a decline in anti-CD154 mAb concentration to levels too low to inhibit costimulatory functions; and 3) activation of the alloreactive CDS' T cells during graft rejection following deliberate depletion of regulatory CD4(+) T cells. Rejection of healed-in allografts in tolerized mice appears to be a dynamic process dependent on the level of residual costimulation. blockade, CD4(+) regulatory cells, and activated alloreactive CD8(+) thymic emigrants that have repopulated the periphery after tolerization.
引用
收藏
页码:6623 / 6630
页数:8
相关论文
共 43 条
[1]   Testing time-, ignorance-, and danger-based models of tolerance [J].
Anderson, CC ;
Carroll, JM ;
Gallucci, S ;
Ridge, JP ;
Cheever, AW ;
Matzinger, P .
JOURNAL OF IMMUNOLOGY, 2001, 166 (06) :3663-3671
[2]   Vigorous allograft rejection in the absence of danger [J].
Bingaman, AW ;
Ha, J ;
Waitze, SY ;
Durham, MM ;
Cho, HR ;
Tucker-Burden, C ;
Hendrix, R ;
Cowan, SR ;
Pearson, TC ;
Larsen, CP .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :3065-3071
[3]  
Blazar BR, 1997, J IMMUNOL, V158, P29
[4]  
Clark LB, 1996, ADV IMMUNOL, V63, P43
[5]   Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning [J].
Durham, MM ;
Bingaman, AW ;
Adams, AB ;
Ha, JW ;
Waitze, SY ;
Pearson, TC ;
Larsen, CP .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :1-4
[6]   Primate skin allotransplantation with anti-CD154 monotherapy [J].
Elster, EA ;
Xu, H ;
Tadaki, DK ;
Burkly, LC ;
Berning, JD ;
Baumgartner, RE ;
Cruzata, F ;
Patterson, NB ;
Harlan, DM ;
Kirk, AD .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :675-676
[7]   IN-VIVO CD40-GP39 INTERACTIONS ARE ESSENTIAL FOR THYMUS-DEPENDENT HUMORAL IMMUNITY .2. PROLONGED SUPPRESSION OF THE HUMORAL IMMUNE-RESPONSE BY AN ANTIBODY TO THE LIGAND FOR CD40, GP39 [J].
FOY, TM ;
SHEPHERD, DM ;
DURIE, FH ;
ARUFFO, A ;
LEDBETTER, JA ;
NOELLE, RJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1567-1575
[8]   Immune regulation by CD40 and its ligand GP39 [J].
Foy, TM ;
Aruffo, A ;
Bajorath, J ;
Buhlmann, JE ;
Noelle, RJ .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :591-617
[9]   Mixed chimerism and tolerance without whole body irradiation in a large animal model [J].
Fuchimoto, Y ;
Huang, CA ;
Yamada, K ;
Shimizu, A ;
Kitamura, H ;
Colvin, RB ;
Ferrara, V ;
Murphy, MC ;
Sykes, M ;
White-Scharf, M ;
Neville, DM ;
Sachs, DH .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (12) :1779-1789
[10]  
GARVEY JS, 1977, METHOD IMMUNOL, P347